Bas D. Koster - Concepedia

Author

Bas D. Koster

Amsterdam UMC Location Vrije Universiteit Amsterdam ORCID

Also Known As

B Köster, B. Koster, B. Köster, Bas D Koster, Bas D. Koster, Bas Koster

Publications

553

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam Amsterdam University Medical Centers Cancer Center Amsterdam Janssen (Belgium)Janssen (Netherlands)

About

Bas D. Koster is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam.

Bas D. Koster

Publications

421

Citations

H-Index

Page 1

	Year	Citations
High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer A. Marijne Heeren, Bas D. Koster, Sanne Samuels, Cancer Immunology Research	2014	112
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter, Clinical Cancer Research	2017	62
Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation Berbel J.R. Sluijter, Mari F.C.M. van den Hout, Bas D. Koster, Cancer Immunology Research	2015	61
Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence Mari F.C.M. van den Hout, Bas D. Koster, Berbel J.R. Sluijter, Cancer Immunology Research	2017	50
Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T <sub>reg</sub> reduction and effector T cell activation Kim M. van Pul, Jessica C.L. Notohardjo, Marieke F. Fransen, Science Immunology	2022	48
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Blood	2024	31
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A<sup>+</sup>CD141<sup>+</sup> cDC1 and CD14<sup>+</sup> antigen-presenting cell recruitment Bas D. Koster, Marta López González, Mari F.C.M. van den Hout, Journal for ImmunoTherapy of Cancer	2021	21
Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial Bas D. Koster, Saskia J. Santegoets, Jorien Harting, Cancer Immunology Immunotherapy	2019	19
Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies Anita D’Souza, Luciano J. Costa, Jesús F. San Miguel, Blood	2024	17

Page 1